15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Vanda Pharmaceuticals Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $7.50 to $21.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $14.30 sits 177% above the current $5.16. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.51 next quarter toward $-0.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Vanda Pharmaceuticals Inc.
As of Jul, 4 of 5 firms rate VNDA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VNDA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.51
Range $-0.60 – $-0.36 · 4 analysts · +34% YoY
Next period, 4 analysts expect Vanda Pharmaceuticals Inc to earn $-0.51 a share (range $-0.60 – $-0.36), versus $-0.38 a year earlier. Full-year consensus is $-2.27, growing to $-0.77 the year after.
REVENUE · NEXT QUARTER
$69.2M
Range $64.9M – $72.7M · 4 analysts · +23% YoY
Revenue is expected to reach $69.2M (range $64.9M – $72.7M), +22.9% year-over-year. Full-year consensus is $262.1M, rising to $356.5M next year.
Top analysts covering Vanda Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VNDA.
#1
Charles Duncan
Cantor Fitzgerald · Rank #188
Buy
$13.00+151.9% to target
Overall win rate
42%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$21.00+307.0% to target
Overall win rate
37%
+ Follow
#3
ME
Madison El-Saadi
B. Riley Securities
Buy
$14.00+171.3% to target
Coverage
—
+ Follow
#4
OB
Olivia Brayer
Cantor Fitzgerald
Buy
$11.00+113.2% to target
Coverage
—
+ Follow
#5
LS
Les Sulewski
Truist Securities
Buy
$18.00+248.8% to target
Coverage
—
+ Follow
VNDA stock forecast FAQ
What is VNDA's average 12-month price target?+
The 5 analysts with a live target average $14.30 for Vanda Pharmaceuticals Inc over the next 12 months, ranging from a $21.00 high to a $7.50 low.
Is VNDA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VNDA?+
The Street-high target is $21.00 (HC Wainwright & Co.), and the Street-low is $7.50 (Jefferies). The average of all 5 active targets is $14.30.
How many Wall Street analysts cover VNDA?+
5 analysts have an active rating on Vanda Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering VNDA?+
Among analysts who currently cover VNDA, Charles Duncan of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #188). Their current call is Buy with a $13.00 target.
What is Vanda Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.51 per share (range $-0.60 – $-0.36) across 4 analysts. Full-year EPS is projected at $-2.27, rising to $-0.77 the following year.
How much revenue is Vanda Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $69.2M (range $64.9M – $72.7M). Full-year revenue is projected at $262.1M, growing to $356.5M next year.
Have analysts been upgrading or downgrading VNDA lately?+
As of Jul, 4 of 5 firms rate VNDA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VNDA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
